OPCI story
In 2010 we decided to construct our Egyptian National pharmaceutical company with international
standards in the new orientation. Not to be me-too products but to add value to the
pharmaceutical market facing the challenges and satisfying the market with highly needed
pharmaceutical products.
We started with our first challenge to introduce desmopressin acetate the (ADH hormone analog)
with know-how in its registration and we succeeded to overcome this challenge and introduced
Omegapress in 2019 which fills the gap in the treatment of central diabetes insipidus, nocturnal
enuresis, and Nocturia.
Omegacough (levodropropizine) the first peripheral antitussive that does not affect the
cough center is a safe product for children.
Dostilact (Cabergoline) reduces the level of
prolactin hormone that may cause infertility. and we still have more than 35 products in our
pipeline to be introduced one by one.